Evidence map›Paper›PMID 36600325›Full record

ArticleBMJ open2022

Multicentre, randomised, economic evaluation of a web-based interactive education platform, simple or enhanced, for patients with end-stage renal disease: the PIC-R trial protocol.

Evangeline Pillebout, Isabelle Durand-Zaleski, Louis Farge, Lionel Perrier, Clement de Chaisemartin, J C K Dupont, Luc Behaghel, Lise Rochaix, Paris School of Economics and AP-HP Hospinnomics, Paris, France

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03090828 (Economic Evaluation of an Interactive Community-based Patient Education Platform Kidney Dialysis and Transplantation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03090828 naunknown statusnot on this map

Economic Evaluation of an Interactive Community-based Patient Education Platform Kidney Dialysis and Transplantation

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2017 to 2022Enrolled1,600ConditionsEnd-stage Renal Disease, Dialysis, Kidney TransplantationArmsapp-based therapeutic education, enhanced app-based therapeutic education
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Evangeline Pilleboutnephrology, Assistance Publique - Hopitaux de Paris, Paris, France.
Isabelle Durand-ZaleskiUniversity of Paris, Paris, France isabelle.durand-zaleski@aphp.fr.ORCID 0000-0002-4078-1476
Louis FargeDocmadi, Clamart, France.
Lionel PerrierDirection of Clinical Research and Innovation, Centre Leon Berard, Lyon, France.ORCID 0000-0003-4487-8723
Clement de Chaisemartineconomics, Sciences Po, Paris, France.
J C K DupontParis School of Economics, Paris, France.
Luc BehaghelParis School of Economics, Paris, France.
Lise Rochaix
Paris School of Economics and AP-HP Hospinnomics, Paris, France

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEnd-stage renal disease (ESRD) affects 84 000 persons in France and costs an estimated €4.2 billion. Education about their disease empowers patients and allows improved management of their disease and better health outcomes. This study aims to explore whether the addition of an interactive web-based platform to patient education is effective and cost-effective and additionally whether complementing the platform with social functions and features improves its performance. METHODS AND ANALYSIS: Patients with severe, ESRD or post-transplant will be randomised 1:1:1 to either standard therapeutic education; or education using a specific application; or the enhanced interactive app with social features. The total follow-up duration is 18 months. Primary endpoint is the cost utility of using app-based therapeutic intervention; secondary endpoints are: compliance with treatment guidelines, app use (professionals and patients), patients' satisfaction, budget impact analysis. ETHICS AND DISSEMINATION: The findings will inform the deployment and reimbursement of the application. The study has ethical approval by the Ile de France ethics committee. Dissemination of the results will be presented at conferences and in peer-reviewed publications. TRIAL REGISTRATION NUMBER: NCT03090828.

Indexed as

Kidney Failure, ChronicPatient ComplianceCost-Benefit AnalysisFranceHumansInternetMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical trialsHealth economicsHEALTH ECONOMICSNephrologyProtocols & guidelinesTelemedicine

Identifiers

PMID36600325
PMCPMC9763667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.